Pipeline victories are accelerating Takeda into a new launch cycle
- Takeda is shifting its focus to New Launches to offset the loss of older drug revenue.
- ENTYVIO Pen now has formulary access with all three large U.S. pharmacy benefit managers.
- The late-stage pipeline is derisking with ORZEYFUL approved in China and zasocitinib beating rivals in Phase III.
- Takeda secured sole global rights to commercialize rusfertide.
- Softening Albumin demand in China is a longer-term structural challenge driven by government guidelines.
A cleaner handoff
Takeda is in the middle of a hard handoff. Older products are fading, led by VYVANSE after generic copies entered the market. At the same time, newer medicines are growing. Management is formally retiring the old Growth and Launch category to refocus the company purely on New Launches and Core In-line Brands.
The thesis has improved. Management said the VYVANSE hit peaked in the first half of FY2025, and later confirmed cost control fully offset the profit impact. That matters because it gives Takeda room to fund launches without letting margins collapse.
ENTYVIO is the key bridge. The Pen version now has access with all three large U.S. pharmacy benefit managers, with more than 80% commercial coverage. That helps U.S. growth stabilize after earlier payer access problems.
The bull case rests on the pipeline, which is actively derisking. ORZEYFUL is now approved in China for narcolepsy. Takeda gained sole global rights to rusfertide, and zasocitinib showed clear superiority over deucravacitinib in a Phase III psoriasis study. If these upcoming launches succeed, they can help offset ENTYVIO biosimilar pressure expected in the 2030s.
Patents fund the pipeline
Takeda makes money by selling prescription drugs, vaccines, and plasma-derived therapies. Many of its best products are protected by patents, special manufacturing know-how, or strong doctor use. When protection ends, generic or biosimilar rivals can take share and cut prices fast.
The company is trying to replace older revenue with a fresh wave of assets. The new focus is on products that are within five years of launch, ensuring the pipeline constantly refreshes the top line.
Cost cuts are a major part of the model right now. Management is using an enterprise-wide efficiency program and expects core operating profit margins to improve by 100 to 250 basis points annually from FY2025. A basis point is one one-hundredth of a percentage point.
There is a tradeoff. Takeda is cutting costs while preparing major launches. The earlier decision to cut cell therapy efforts shows a focus on prioritizing the most promising late-stage assets.
What carries the story
ENTYVIO
ENTYVIO treats inflammatory bowel disease. Its Pen version now has more than 80% U.S. commercial coverage, which reduces a key access risk.
VYVANSE
VYVANSE treats ADHD and is facing generic erosion. Takeda lost significant revenue here, but management says the worst pressure is tapering.
Plasma-Derived Therapies
This business sells therapies made from human plasma. Subcutaneous immunoglobulin is growing well, but Albumin demand in China is structurally challenged by new government guidelines.
QDENGA
QDENGA is Takeda's dengue vaccine. It is growing rapidly, driven mainly by demand in Brazil.
ORZEYFUL
ORZEYFUL, formerly oveporexton, is a narcolepsy type 1 drug. It recently received approval in China, with U.S. and Japan milestones expected soon.
Rusfertide
Rusfertide is aimed at polycythemia vera, a blood disorder. Takeda now holds sole global rights to commercialize the drug following positive Phase 3 data.
Zasocitinib
Zasocitinib is a psoriasis drug candidate that recently demonstrated statistical superiority over a key rival in Phase III testing.
Where revenue comes from
The mix uses fiscal year 2025 business-area revenue for the year ended March 31, 2026. Gastroenterology is the largest area.
What could break it
ENTYVIO competition
High impact · Medium oddsENTYVIO is central to Takeda's bridge from old drugs to new launches. Biosimilar rivals are an emerging risk in Europe. Takeda points to patents that run into 2032, but filings by rivals make this a live issue.
Launch cycle execution
High impact · Medium oddsORZEYFUL, rusfertide, and zasocitinib carry a large part of the bull case. While clinical data is strong, regulatory approval, labeling, pricing, and doctor adoption still have to go right. A weak launch would leave Takeda exposed to older product pressure.
Albumin softness in China
Medium impact · High oddsTakeda's plasma business is mixed. Albumin demand in China softened, driven by new government utilization guidelines. This turns a short-term issue into a longer-term structural headwind.
U.S. pricing pressure
Medium impact · High oddsU.S. Medicare Part D redesign and 340B expansion create near-term gross-to-net pressure, meaning more rebates and discounts come off list prices. The longer-term drug pricing rules may add more pressure.
In one breath
Why is Takeda stock tied to VYVANSE?
VYVANSE used to be a major profit source, but generic versions are now taking share. The good news for Takeda is that management says the sharpest part of the erosion has passed.
What is Takeda's most important drug?
ENTYVIO is the key product to watch because it is large, still growing, and central to the transition plan. Its U.S. Pen access has improved, but future biosimilar competition is a major risk.
What are Takeda's next big launches?
The main late-stage launches are ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. ORZEYFUL is already approved in China.
